TABLE 3.
Hospital Morbidities at Discharge for the THOP Trial According to Treatment Arm
| Placebo (N = 27) |
Iodine (N = 24) |
Bolus 4 μg/kg per d (N = 24) |
Continuous 4 μg/kg per d (N = 24) |
Bolus 8 μg/kg per d (N = 20) |
Continuous 8 μg/kg per d (N = 25) |
Total (N = 144) |
|
|---|---|---|---|---|---|---|---|
| Discharge weight or at death, mean ± SEM, g | 2973 ± 238 | 2653 ± 162 | 2346 ± 93 | 2596 ± 167 | 2134 ± 186 | 2338 ± 167 | 2521 ± 74 |
| Median | 2630 | 2620 | 2235 | 2302 | 2300 | 2400 | 2473 |
| Range | 1190–6335 | 750–4100 | 1235–3260 | 910–4600 | 850–3275 | 820–3840 | 750–6335 |
| Duration of ventilator, mean ± SEM, d | 38 ± 145 | 19 ± 5 | 14 ± 3 | 9 ± 2a | 13 ± 3a | 20 ± 4 | 19 ± 3 |
| Median | 11 | 9 | 5 | 5 | 10 | 12 | 8 |
| Range | 0–300 | 0–95 | 0–51 | 0–39 | 0–35 | 0–78 | 0–300 |
| Duration of CPAP, mean ± SEM, d | 23 ± 4 | 19 ± 3 | 22 ± 3 | 25 ± 3 | 24 ± 5 | 27 ± 4 | 23 ± 2 |
| Median | 18 | 19 | 23 | 27 | 20 | 25 | 23 |
| Range | 0–100 | 0–45 | 0–52 | 0–43 | 0–83 | 0–56 | 0–100 |
| Duration of hospital stay, mean ± SEM, d | 100 ± 12 | 88 ± 8 | 76 ± 6 | 83 ± 7 | 67 ± 8 | 82 ± 6 | 83 ± 4 |
| Median | 84 | 89 | 77 | 82 | 64 | 75 | 82 |
| Range | 18–343 | 15–210 | 7–116 | 10–146 | 10–133 | 25–132 | 7–343 |
| Death at >7 d, n (%) | 4 (15) | 4 (17) | 2 (8) | 2 (8) | 6 (30) | 4 (16) | 22 (15) |
| ROP ≥ stage 3, n (%) | 5 (19) | 4 (17) | 1 (4) | 2 (8) | 0 (0)a | 2 (8) | 14 (10) |
| NEC ≥ stage 2, n (%) | 2 (7) | 2 (8) | 1 (4) | 1 (4) | 3 (15) | 6 (24)a | 15 (10) |
| GM/IVH, n (%) | 9 (36) | 7 (29) | 3 (13) | 8 (33) | 7 (39) | 7 (32) | 41 (30) |
| White matter damage, n (%) | 3 (12) | 2 (8) | 0 (0)a | 2 (8) | 3 (17) | 2 (9) | 12 (9) |
| CLD, n (%) | 12 (44) | 8 (33) | 11 (46) | 5 (21) | 6 (30) | 9 (36) | 51 (35) |
| Combined arms: mortality, % (n/N) | 16 (8/51) | 8 (4/48) | 22 (10/45) | ||||
| Combined arms: ROP > stage 3, % (n/N) | 18 (9/51) | 6 (3/48) | 4 (2/45) | ||||
| Combined arms: NEC, % (n/N) | 8 (4/51) | 4 (2/48) | 20 (9/45)a | ||||
| Combined arms: GM/IVH, % (n/N) | 31 (16/51) | 23 (11/48) | 31 (14/45) | ||||
| Combined arms: white matter, % (n/N) | 10 (5/51) | 4 (2/48) | 11 (5/45) | ||||
| Combined arms: CLD, % (n/N) | 39 (20/51) | 33 (16/48) | 33 (15/45) | ||||
CPAP indicates continuous positive airway pressure; GM, germinal matrix.
a
The occurrence of the sign or the mean of the variable in this arm is significantly different from that across all study arms; P < .05.